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ABSTRACT 
At the air-water interface, the tear film lipid layer (TFLL), a combination of lipids and proteins plays an important role in surface tension of the tear 
and is necessary for the physiological hydration of the ocular surface and maintenance of ocular homeostasis. Alteration in lacrimal fluid rheology, 
differences in lipid constitution or down regulation of particular tear proteins are found in maximum types of ocular surface disease including dry 
eye disease (DED). Dry eye is a disorder of the tear film due to tear deficiency or excessive tear evaporation, which causes damage to the 
interpalpebral ocular surface and is associated with symptoms of discomfort. It results in changes on the ocular surface epithelia causing reduced 
tear quantity and surface sensitivity which leads to inflammation reactions. Managing this inflammation is very helpful in dry eye disease patients. 
In this article we revise the current understanding of tear film properties, ocular surface and review the effectiveness of topically applied tear 
supplements, thermo sensitive atelocollagen punctal plug, subtrasal ultrasonic transducers, novel liposome based gelling tear formation and insulin 
based ophthalmic delivery systems which help in restoring the healthy tear film.  
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Dry eye syndrome is a multifactorial disease affecting lacrimal gland 
and ocular surface causing discomfort, blurring of vision, instability 
of the tear film and with latent destruction of the ocular surface. It is 
often accompanied by increased osmolarity of the tear film and 
inflammation of the ocular surface. Dry eye disease is categorized 
into aqueous-deficient (equating with reduced lacrimal gland 
function) and evaporative (equating very largely with meibomian 
gland dysfunction) dry eye disease. Evaporative dry eye is prevalent 
than aqueous-deficient dry eye, and patients develop both the form 
concomitantly [1]. The dry eye disease is a condition characterized 
by dryness in eye which causes an uncomfortable feeling and 
worsens over time. In 2014, dry eye was prevalent in 11% of the 
population in Spain where 11.9% of women and 9% of men were 
affected. Dry eye disease occurs due to decreased tear secretion, 
reduction in volume of tear on corneal surface as well as conjunctiva 
surface and increased evaporation of tear also causes dryness of eye 
[2, 3]. 
The exocrine gland continuously produces aqueous fluid which 
helps in maintaining the wetness on the ocular surface and is 
adjusted by blinking rate and environmental factors. [4]. Irritation in 
the eye also increases the tear secretion. The polymodal-nociceptor 
and mechan-o-receptor nerve endings are sensitive to irritants and 
thus detects and responds to the stimuli [5]. 
Clinical features of dry eye disease include eye fatigue feeling, 
keratoconjunctival epithelial disorder, dryness, ocular discomfort, 
hyperemia and abnormalities in vision. Dry eye disease is caused 
due to increased usage of VDT (video display terminal in television, 
personnel computer monitors), ageing, irritants, vitamin A 
insufficiency, rheumatologic disease, chemical and thermal burns, 
rheumatoid arthritis and also due to drugs such as levoblastin, 
oxybutynin, atenolol, levofloxacin, hydrochlorothiazide.  
Treatment of dry eye disease 
Cyclosporine A  
Cyclosporine A was one of the first treatment for dry eye disease. It 
has shown the property to reduce the inflammation in the ocular 
surface and also targets the symptoms of dry eye disease.0.05% and 
0.1% concentrations of Cyclosporine A are the appropriate 
concentrations used in treatment of dry eye disease.  
A study was carried out to study the safety and efficacy of topically 
administered 0.05% cyclosporine A twice a day for the treatment of 
severe to moderate dry eye. The study showed improvement in the 
dry eye condition with time [6]. Sjoren Syndrome also leads to dry 
eye condition, the condition of which can be treated by Cyclosporine. 
It inhibits the cytokine receptors and reduces the inflammation thus 
aids in treating dry eye disease [7]. 
Ophthalmic emulsion of cyclosporine A was used to carry out study 
on dry eye syndrome for over 6 mo. The result was increase in 
number of goblet cells among the patients. The patients with or 
without systemic studies showed improvement in dry eye disease 
[8-10]. Thus 0.05% cyclosporine was patient compliant as it showed 
improved results within 3 to 6 mo. 
Hydroxypropyl cellulose ophthalmic inserts  
Opthalmic insert is a solid or semisolid consistency device placed into 
the cul-de-sac or conjuctival sac which is thin, multi-layered, drug-
imbued and most importantly sterile. The shape and size of the ocular 
inserts are specifically crafted for ophthalmic drug delivery. Inserts are 
mainly constituted by polymers with or without any medicament [11]. 
The core objective of the ocular inserts is to enhance the residence 
time as well as the contact time between the formulation and the 
conjunctival tissue in order to provide a sustained release suitable for 
the treatment either topically or systemically. Ophthalmic inserts are 
an alternative treatment option applicable in the treatment of 
moderate-to-severe dry eye syndrome [12-14]. 
The ophthalmic inserts are the means of ophthalmic drug delivery 
system that need to be sterile. They are in the form of translucent 
rods measuring 1.27 mm in diameter and 3.5 mm in length. Each 
ophthalmic insert consists of 5 mg hydroxypropyl cellulose, without 
any preservative and other excipients. The insert is administered 
into the eye by placing it into the inferior cul de sac cavity of the eye 
underneath the base of the tarsus, not in opposition to the cornea, 
nor beneath the eyelid at the level of the tarsal plate. The mechanism 
of action of Hydroxypropyl cellulose ocular inserts is by stabilizing 
and thickening the tear film and extending tear film breakup time 
(TBUT). In addition, it also lubricates and protects the eye. 
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Fig. 1: Classification of ocular inserts 
 
 
Fig. 2: Structural components of ocular inserts 
 
The ocular inserts are designed particularly for the patients who 
possess dry eye indications even after a sufficient therapy with the 
use of artificial tears. The inserts can also be administered by the 
patients suffering from keratoconjunctivitis sicca, exposure keratitis, 
decreased corneal sensitivity, and recurrent corneal erosions. 
Hypersensitivity reactions to Hydroxypropyl cellulose is the only 
drawback of this therapy [15] 
Hyaluronic acid based eye drops 
The three layers on the preocular tear film are the outer tear film 
lipid layer, clear tear film aqueous layer and inner tear film mucin 
layer [16, 17]. Hyaluronic acid has a viscoelastic rheology and is an 
anionic glycosaminoglycan mostly found in aqueous humor and 
vitreous humor. Hyaluronic acid based eye drops are coated around 
the corneal endothelium since it offers a lubricating effect and also 
offers resistance to dehydration, effectively binds to water and has 
good biocompatibility [18, 19]. Artificial tear eye drops of HA can be 
used to stabilize the preocular tear film, improve the irregularity on 
the ocular surface and reduce the symptoms of dry eye [20-22]. A 
study was done to compare the efficacy of preservative free 0.1% 
HA, 0.18% HA and 0.3% HA artificial tear drops in the mouse model 
withering stress induced environmental and pharmacological 
experiment in dry eye disease. It displayed better protection of 
corneal epithelial cells compared to HPMC and CMC [23] and also 
better lubricant property by retaining moisture and acted as 
reservoirs in slowly releasing water molecules [24].  
The frequently employed test for examining the tear film 
abnormality is the measurement of tear break up time (TBUT). 
TBUT is the time interval between the end completion of blink and 
first break in tear film [25]. The TBUT upon administration of HA 
shows improved stability of the tear film, reduced evaporation and 
hyperosmolarity in the tear film due to the property of water 
retention by HA [26].
Thermosensitive atelocollagen punctal plug  
 0.3% of HA showed significant activity on 
TBUT when compared to 0.18 and 0.1% HA. The higher 
concentration of HA also exhibited better corneal surface healing 
[27]. The goblet size density in conjunctiva was high on 
administration of 0.3% HA and 0.18%HA compared to 0.1% HA. The 
inflammation on the ocular surfaces decreases with increase in the 
goblet size [28]. Thus 0.3% HA was most effective when compared 
to 0.18% and 0.1% HA in the treatment of dry eye disease. 
The punctual plug has shown positive effects in treatment of 
aqueous tear deficit dry eye disease like neurogenic dry eye which 
is caused due to photorefractive ketacomy and (LASIK), dry eye 
caused due to contact lenses [29-31]. The punctual plugs are 
categorized into absorbable and non-absorbable plugs. Absorbable 
plugs are used in the treatment of temporary dry eye disease. For 
example, post-LASIK dry eyes. It can also be used in evaluating non 
absorbable plugs. Collagen punctal plug is an example for 
absorbable plug and it shows similar effect silicone plugs [32, 33]. 
Non Absorbable plugs like Freeman plug is the frequently used 
non absorbable plug available in various sizes which helps in 
fitting into various dry eye treatments [34-36]. It offers high 
stability and safety but also has few problems such as corneal 
irritation, epithelial laceration, frequent extrusion and granules 
formation. 
Thermosensitive atelocollagen punctal plug (Keeptear) is recently 
been developed and under usage in Japan. It is an absorbable plug 
available in syringe, liquid at room temperature which turns into gel 
at body temperature so as to fit well in the patient’s punctum. It is to 
be injected in to the patient’s canalicus from the punctum. The 
keeptear is kept out for 15 min after taking out of refrigerator before 
injection. The atelocollagen turns into liquid state in 7 min when 
heated to 43 °C but the crystal structure collapsed, thus 41 °C with 8 
min of heating was chosen to be suitable preheating condition. 
Keeptear blocks the canaliculi and retains the volume of tear for 
about 1 mo. It offers drawbacks such as its inability to confirm the 
localization of the plug post insertion and temporary effect in 
relation to punctal occlusion. It is best suited for seasonal worsening 
of dry eye and postsurgical dry eye [37]. Complications such as 
blurred vision, irritation, pain, foreign body sensations were not 
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found when Keeptear was used. Thus the Keeptear was found to be 
safe and effective. 
Subtarsal ultrasonic transducers for mild hyperthermia 
treatment  
Meibomian glands are sebaceous glands present in upper and lower 
eye lids present 20 to 25 in numbers [38]. They secrete meibum 
which constitutes the lipid part of the tear that act as hydrophobic 
seal [39]. The secretion slows down the evaporation rate and 
increases the film stability. The meibomian lipid is present in liquid 
form in 36 °C [40]. But in patients with meibomian gland 
dysfunction, the meibum is secreted with abnormal elevated 
temperature by 3 ° C to 4 °C. This condition affects the secretion of 
meibomain lipid from meibomian ducts [41]. 
A recent study was conducted on the design and practicability of 
ultrasound device in mild hyperthermia in tarsal plate. The 
temperature of meibomian glands present in inner eyelid is increased 
by the device to the melting point of abnormal meibomian lipid, 
assumed to be 41 °C to 43 °C. The treatment last for 5 to 15 min. The 
frequency of the treatment depends on the severity of the patient.
 
 
Fig. 3: Experimental design for hyperthermia experiments conducted in vivo. T1 and T2 indicates the temperatures of the humor and 
eyelid, which is measured by thermocouples embedded in the tissue 
 
The hyperthermia therapy conducted for obstructive meibomian 
gland dysfunction is by liquefying the keratinized meibum present in 
meibomian gland thus elevating the temperature of glands by 5 °C to 
7 °C (41 °C to 43 °C). This leads to secretion of meibum with 
increased stability and it avoids to evaporation of the tear from the 
ocular surface. This is due to its hydrophobic coat formation [42]. 
The heat induced is directly applied or effected to meibomian gland 
which is present at the Centre of inferior and the superior eyelid. 
Even though the diffusion of heat occurs by itself, more studies are 
required to know the spatial distribution of heat [43] 
Design of ultrasonic transducer 
The contact lens is embedded with piezo-electric transducers where 
an air gap is present internally. The air gap helps in providing the 
transducers with air backing. The transducers are fixed reflexively 
onto the posterior tarsal face. The acoustic waves gets reflected 
towards tarsus and then reflected away from cornea which prevents 
the cornea from heating due to direct application of ultrasound [44]. 
A recent in vivo study was conducted on porcine subject where an 
equilibrium rise in temperature (5 ° C to 8 °C) was observed in 10 to 
15 min. It was also found that the perfusion rate of blood reduced 
with time. Not more than 2 °C rise was seen in the corneal 
temperature. No evidence of corneal damage was found in the 
experiments. 
Tear supplements 
Carboxymethyl cellulose-glycerin-castor oil (cCGC) depicted the 
greatest trend in reducing the inflammatory biomarkers. After 4 w 
of treatment, 40% of the subjects showed positive response. By the 
use of CMC, 10% of the patients showed positive response while the 
use of HPG showed no positive response. The stress levels in 
induced cellular hyperosmolarity was significantly reduced in CGC 
formulation in cell models and animal models [45-47]. The test was 
conducted to check its effect in Sjoren Syndrome, allergic eye 
disease, amblyopia and glaucoma, thus treatment effect and 
responsive index was determined [48-50] 
 
 
Fig. 4: Repeated measures study design. Each subject completed this program of visits with a 1 w washout duration before starting 
treatment 1 and a 1 w washout between treatments 
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A recent study was carried out on Interleukin 6 (IL-6) and matrix 
metallopeptidase 9 (MMP-9) levels in human with two artificial tears. It 
was found that the osmoprotectants and CMC reduced the inflammation 
levels [51, 52]. Castor oil upon instillation has reported the ocular 
residence time of 4 h [53, 54]. After the instillation of artificial tears, the 
treatment period must be prolonged for 2 to 4 w in order to significantly 
affect the cytokine levels to reduce the inflammation. Compared to anti-
inflammatory medications, the osmoprotectants show rapid mechanism 
within 2 w [55] However, longer duration of treatment has shown 
reduction in dry eye in murine model used in corneal staining and 
testing the goblet cell density [56]. 
The artificial tears are inclusive of preservatives. For example, CMC 
eye drops contained purite as preservative that causes the natural 
tear components to break down [57]. In animal model it shows very 
less epithelial erosion. Polyquad, a preservative used in HPG eye 
drops shows minimal effect in reducing the inflammation [58-60] 
Novel liposome-based and in-situ gels 
Restoring the tear film is one of the main objectives in treatment of 
dry eye disease. The novel artificial tear is formulated in such a way 
that it resembles the natural tear. Liposomes which contains 
phosphatidylcholine and cholesterol where used to restore the lipids 
in tear film. Gellan gum polymer has to feature of forming gel when 
it comes in contact with some ions which are present in the tear [61-
63]. This gel prevents the loss of tear and increase the resistance 
time of the formulation with the help of Hydroxyproply methyl 
cellulose (HPMC) which increases the bio-adhesion [64, 65]. To 
increase the effectiveness of artificial tears antioxidants like vitamin 
A and vitamin B, trehalose, osmoprotectants can be incorporated. 
The main physicochemical parameters to be considered include 
viscosity, pH and surface tension. Viscosity ranges from 1.0-8.3mPas 
[66, 67]. If the viscosity increases then it might cause blurred vision, 
ocular discomfort and formulation instability due to non-uniform 
mixing with natural tears. The pH of human tear is 7.0 to 7.5 and due 
to the buffering capacity, the pH of the formulation can be adjusted 
accordingly as required to reduce the discomfort in eyes [68, 69]. 
The surface tension of tears ranges between 40-46 mN/m [70, 71]. It 
is an important parameter to consider as it interacts with the tear 
film and could affect the spread on the ocular surface [72]. 
If all the above parameters are in proper levels (pH-7.6, viscosity-
4mPas, surface tension-53.4mN/m) a good formulation can be 
developed. The liposomal nano-particles must also possess suitable 
size for formulation as artificial tears. The artificial tear did not show 
any toxic effects on both J774 and HeLa cell lines. It didn’t cause any 
discomfort in the rabbits and showed better in vivo tolerance. The 
novel liposomal artificial tear showed a good potential to replenish 
the tear, protect the corneal epithelium and successfully treat the 
dry eye disease. Due to its gelling property it showed good property 
to develop as a formulation for ophthalmic administration. 
Prospective insulin based ophthalmic delivery systems 
Diabetes mellitus (DM) could be one of the reasons for dry eye disease 
condition because they lead to complications like diabetic retinopathy, 
cataract which leads to the alterations on ocular surface and affects the 
functioning of the lacrimal gland (LG) [73-75]. This condition leads to 
reduction in the volume of tear secretion due to the condition of diabetes 
mellitus the disruption on ocular surface will not be healed easily which 
leads to inflammation and dry eye syndrome [76, 77]. 
Insulin receptors are present on the ocular surface and the lacrimal 
gland thus this approach can be used for healing the corneal surface 
[78]. Application of insulin on the ocular surface topically is a good 
strategy but the drawback of this is the reduced resident time on the 
ocular surface because of mechanisms such as drug dilution, tearing 
and reduced bioavailability [79]. Invasive release systems can be 
used for administration of insulin through implants, aqueous 
solutions [80]. 
Micro particulate delivery systems show better drug delivery 
compared to the nanoparticles [81]. They are made to increase their 
resistance time on the ocular surface by incorporating them along 
with a in situ thermo reversible gel which stays in aqueous state 
where its viscosity will be same as the conventional eye drops in the 
room temperature and when it comes in contact with the ocular 
surface it turns into gel form. This gel increases the resistance time 
on the ocular surface and increases the mechanical strength and 
prevents the drug leakage [82]. 
Chitosan possess good biocompatibility, biodegradability, 
penetration and mucoadhesion which help in increasing the 
bioavailability. Thus, it can be used as polymer in preparation of 
microparticles. Opposite charges exists between insulin (negative) 
and chitosan (positive) [83], which helps in incorporating the insulin 
into the microparticles. Polyelectrolyte complexation is used to 
prepare the chitosan microspheres [84]. 
Incorporation of the insulin into the chitosan polymeric 
microparticles did not make significant difference in the size and 
morphology compared to conventional eye drop. The microparticles 
have micrometric size which prevents from blurring of vision [85]. 
No discomfort in the eye was observed. Thus insulin loaded chitosan 
microparticles where having optimum particle size and 
physiochemical characteristics to be used as topical ocular 
formulation. 
Diquafosol ophthalmic solution  
Diquafosol is a P2Y2 purinergic receptor antagonist. It is 
characterized by fluid secretion, increase in the mucin secretion due 
to gradual increase in goblet cells, increase in the hydrophilic 
characteristics on the ocular surface, strengthening of aqueous 
mucin layer, increase in the gene expression of membrane binding in 
corneal epithelial cells and tear film stabilization [86,87]. Diquafosol 
ophthalmic solution (3% w/v) on topical instillation show positive 
action towards both type of dry eye disease-aqueous tear deficient 
dry eye (ADDE) and evaporative dry eye (EDE). It effectively 
alleviates the symptoms and increases TFBUT among the patients 
with short TFBUT type dry eye where there is observation of 
decreased TFBUT and not much damage of epithelium and avoid the 
dysfunction of lacrimal gland is seen [88]. Application of diquafosol 
for about 1 mo showed the improvement in symptoms of dry eye, 
corneoconjunctival staining and TFBUT. Adverse reactions could be 
observed in 4.3% of patient’s. [89]. Diquafosol can also be used in 
combination with 0.1% hyaluronic solution in formulation and it 
shows better tear stability thus can be used to treat dry eye. 
Diaquafosol exhibits better efficacy in patients with short TFBUT 
type of dry eye caused by environmental stress, long usage of video 
display terminals like television and personal computers etc. [90-
92]. The results of test done on patients with dry eye disease using 
diquafosol (3% w/v) are shown in the table 1. 
 
Table 1: The percentage of patients who showed changes in dry eye symptoms and ocular signs after 4 w of topical administration of 3% 
diquafosol ophthalmic solution 
Changes after treatment in patients No. of patients treated (%) 
Improved No change Worsened 
Subjective dry eye symptom 55 (78.6) 15 (21.4) 0(0) 
Tear film break-up time 46(65.7) 22(31.4) 2(2.9) 
Ocular staining score 44(62.8) 23(32.9) 3(4.3) 
 
CONCLUSION 
Knowledge regarding tear film properties and ocular surface plays a 
key role in the treatment and management of dry eye disease. Tear 
drops, Hyaluronic acid eye drops, thermosensitive atelocollagen 
punctal plug, subtrasal ultrasonic transducers, novel liposome based 
gelling tear formation and insulin based ophthalmic delivery systems 
Jain et al. 
Int J App Pharm, Vol 11, Issue 6, 2019, 30-36 
34 
help in restoring the healthy tear film. 0.3% HA showed better effect 
that 0.18% HA and 0.1% HA. 0.05% Cyclosporine A twice a day for 
over 6 mo showed increase in goblet cells thus treating dry eye. Tear 
supplements like carboxymethyl cellulose-glycerin-castor oil (cCGC), 
carboxymethyl cellulose (CMC), Hydroxypropyl guar (HPG) showed 
positive results in treatment of dry eye disease. Thermosensitive 
atelocollagen punctal plug, Subtrasal ultrasonic transducers and novel 
liposome based in situ gelling tear formation showed good potential to 
replenish the tear, protect the corneal epithelium. 3% diquafosol 
ophthalmic solution on topical instillation show positive action 
towards both the types of dry eye disease. Insulin loaded chitosan 
microparticles regulate the function of lacrimal gland. These available 
treatments have therefore led to improvements in detection and 
management of this common condition, which provides enormous 
benefits to the patients. 
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